血凝酶治疗脑出血早期血肿的临床研究  

Clinical research of hemocoagulase in treatment of haematoma after primary intracerebral hemorrhage

作　　者：何允兰[1] 

机构地区：[1]菏泽市立医院,274031

出　　处：《中国实用医药》2012年第28期17-18,共2页China Practical Medicine

摘　　要：目的探讨血凝酶治疗脑出血早期血肿的疗效。方法将92例患者随机分为治疗组46例和对照组46例,在常规治疗基础上,治疗组给血凝酶1U静脉推注,随机1U肌内注射,对照组应用一般止血药(止血敏2g,止血芳酸0.4加液体静脉滴注),治疗前后分别进行疗效评定。结果治疗组46例中总有效率(89.13%),再出血2例(4.35%,血压均小于160/110mmHg),无消化道出血病例,死亡1例;对照组46例中3例血压均大于160/110mmHg,并发消化道出血5例,(10.87%),死亡3例;两组比较有显著差异性(P<0.05)。结论血凝酶具有良好的止血效果,有利于血肿的减少,控制再出血,不影响患者血凝功能,不会增加血栓危险,治疗脑出血早期血肿安全有效。Objective To investigate the beneficial effects of hemocoagulase atrox in treatment of hae- matoma after primary intracerebral hemorrhage. Methods 92 patients with intracerebral hemorrhage were ran- domly assigned into two groups. 46 patients （ as study group） were mainly treated with hemocoagulase, the oth- er 46 patients（ as control group） were mainly treated with traditionl etamsylate and p-aminomethylbenzoic acid. The management of clinical evaluation curative effect were detected before and after the treatment. Results The effective percentage was 89.13% in study group, 2 cases rehemorrhage, no case appeared bleeding of the gastro intestinal tract, 1 case died. In control group, 5 cases appeared bleeding of the gastro intestinal tract, 31 casse died. There was significant difference in the two groups. Conclusion The treatment of hemocoagulase in patients with haematoma after primary intracerebral hemorrhage is effective. It can reduce haematoma, lower the re-hemorrhage degree and no influence on blood coagulation. Hemocoagulase is safe and effect in in treatment of haematoma after primary intracerebral hemorrhage.

关 键 词：血凝酶 脑出血 早期血肿 

分 类 号：R743.34[医药卫生—神经病学与精神病学]